NeuroSearch investors thrill to trial data
Free newsletter via e-mail
Tools
Shares of NeuroSearch surged on the news that its obesity drug tesofensine produced very good data in a Phase IIb trial. The drug hit all endpoints with a high statistical significance. One analyst dubbed the data "fantastic," which did no harm to the stock value.
- see NeuroSearch's release on the results
Related Articles:
NeuroSearch gains on expanded pact with GSK
NeuroSearch to continue studies for NS2330
SHARE
WITH: